Intraductal Carcinoma of the Prostate: Anonymous to Ominous Melvin L.K. Chua, Theodorus H. van der Kwast, Robert G. Bristow  European Urology  Volume 72, Issue 4, Pages 496-498 (October 2017) DOI: 10.1016/j.eururo.2017.04.004 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Molecular pathological hallmarks of intraductal carcinoma (IDC)–positive prostate cancer. (A) Histomorphology of IDC (labeled) as characterized by a rim of basal cells (brown color) outlining the antecedent prostate duct, distended by carcinoma cells displaying a cribriform architecture. The remaining glands (closed arrows) lacking basal cells are glandular adenocarcinoma. (B) Subclonal reconstruction of BRCA2-mutant (BR samples) and sporadic (CPCG samples) prostate cancers from microdissected IDC and invasive carcinoma components. Both lesions originate from the same clonal ancestry, with subsequent branching to multiple subspecies. MED12L amplification was predominant among BRCA2-mutant tumors; sporadic IDC-positive tumors had a higher frequency of PIK3CA mutations compared to The Cancer Genome Atlas localized prostate cancer cohort [9]. Adapted from Taylor et al [9]. CNA=copy number aberration. European Urology 2017 72, 496-498DOI: (10.1016/j.eururo.2017.04.004) Copyright © 2017 European Association of Urology Terms and Conditions